Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Zafgen, Inc.
Phase 2, randomized, double-blind, placebo-controlled, parallel dose arms study with 12-month randomized treatment.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Obese with BMI ≥30 kg/m2
Type 2 diabetes mellitus
HbA1c of 7-11%
Fasting glucose \<15.5 mmol/L
Treated with diet and exercise alone or with a stable regimen of metformin, sulfonylurea, pioglitazone, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT-2 inhibitor or any combination of these agents
Female subjects must be surgically sterile, post-menopausal or using long-acting contraception, which includes intrauterine devices or use of an implanted or injectable contraceptive
You may not be if
Current or recent use of insulin
Severe hypoglycemia within the prior 6 months
Metabolic disorders or genetic disorders linked to obesity (e.g., Prader-Willi Syndrome)
Clareo Health | An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus
